All In Biotech

Drug Trial Radar · NCT04897958

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14,417

Actual

Start

Sep 21, 2019

Primary completion

Aug 1, 2021

Study completion Aug 1, 2021

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Male only

Summary

As written by the sponsor on the registry.

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Conditions

  • Prostate Cancer

Interventions

  • DegarelixDrug

    Degarelix dispensing claim is used as the reference group.

  • LeuprolideDrug

    Leuprolide dispensing claim is used as the exposure group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Adverse Cardiovascular Events (MACE)Time frame: Through study completion (earliest of 336 days or censoring)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.